Wc500240381 from
BartsMSBlog
Trials are ongoing but as NDG has said "the data may have been less damning if the MRI atrophy data presented ECTRIMS had been positive".
The problem I see for this agent is they they don't really know how it works and this may be a fundamental problem.
The trials have been designed to show that it an agent targeting progressive disease, but based on the early reports it suggested to me that the benefit was either symptomatic or perhaps repair and so the trial design may need to be very different.
Why do I say this?
It was because the reported benefits were occurring quickly.
So could this be another instance of Death of a Drug by Trial Design-meaning perhaps the drug could work but the trial was no designed so that the drug could shine.